JP2017165745A5 - - Google Patents

Claims (13)

  A pharmaceutical composition for promoting muscle regeneration, tendon regeneration or arteriogenesis in a subject, comprising a synthetic peptide consisting of an amino acid sequence having a length of 20 to 39 amino acid residues, wherein the amino acid sequence is SEQ ID NO: Wherein said pharmaceutical composition comprises at least 20 consecutive residues having at least 90% amino acid sequence identity at one residue 11-30.   The pharmaceutical composition according to claim 1, wherein the four consecutive residues of the synthetic peptide are identical to residues 11-14 of SEQ ID NO: 1.   The pharmaceutical composition according to claim 1 or 2, wherein the synthetic peptide has: muscle cell and / or satellite cell proliferative activity; tendon stem cell proliferative activity; and / or arteriogenic activity.   A pharmaceutical composition for promoting muscle regeneration, tendon regeneration or arteriogenesis in a subject, comprising a synthetic peptide consisting of an amino acid sequence having a length of 20 to 39 amino acid residues, wherein the amino acid sequence is SEQ ID NO: The pharmaceutical composition comprising at least a sequence selected from the group consisting of: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 8, and SEQ ID NO: 9.   5. The pharmaceutical composition according to claim 4, wherein the amino acid sequence of the synthetic peptide comprises the amino acid sequence of SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 8, or SEQ ID NO: 9.   5. The pharmaceutical composition according to claim 4, wherein the amino acid sequence of the synthetic peptide comprises the amino acid sequence of SEQ ID NO: 3, SEQ ID NO: 5, or SEQ ID NO: 6.   The pharmaceutical composition according to any one of claims 1 to 6, further comprising a pharmaceutically acceptable carrier.   8. The pharmaceutical composition according to claim 7, wherein the pharmaceutically acceptable carrier is a polymeric material selected from the group consisting of alginic acid, gelatin, collagen, and poly (lactide-co-glycolide).   9. The pharmaceutical composition according to claim 8, wherein the polymer material is alginic acid.   10. The pharmaceutical composition according to any one of claims 1 to 9, which is formulated in a sustained release form.   The pharmaceutical composition according to any one of claims 1 to 10, which is formulated for intramuscular injection.   A synthetic peptide for promoting muscle regeneration, tendon regeneration, or arteriogenesis in a subject, comprising an amino acid sequence having a length of 20 to 39 amino acid residues, the amino acid sequence comprising residues of SEQ ID NO: 1. Said synthetic peptide comprising at least 20 consecutive residues having at least 90% amino acid sequence identity in 11-30.   14.To promote muscle regeneration, tendon regeneration, or arteriogenesis in a subject according to claim 12, wherein four consecutive residues of the synthetic peptide are identical to residues 11-14 of SEQ ID NO: 1. Synthetic peptides.